Acrivon Therapeutics (ACRV) Income Statement (2021 - 2026)
Income Statement report data from Mar 31, 2021 to Mar 31, 2026 for Acrivon Therapeutics (ACRV).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||||||||
Research And Development | 15M (+2.85%) | 15M (+8.06%) | 14M (-15.64%) | 16M (+5.00%) | 15M (-17.28%) | 19M (-1.22%) | 19M (+25.48%) | 15M (+31.04%) | 11M (-25.90%) | 15M (+50.73%) | 10M (-2.38%) | 11M (+7.79%) | 9.76M (-59.25%) | 24M | - | - | - | - | - | - | - |
Selling General And Administrative | 4.74M (-11.73%) | 5.37M (-11.09%) | 6.04M (-6.65%) | 6.47M (+3.52%) | 6.25M (-1.11%) | 6.32M (+0.64%) | 6.28M (-2.03%) | 6.41M (+3.39%) | 6.20M (+11.11%) | 5.58M (-4.94%) | 5.87M (+17.40%) | 5.00M (+7.76%) | 4.64M (-46.73%) | 8.71M | - | - | - | - | - | - | - |
Operating Expenses | 20M (-1.09%) | 20M (+2.18%) | 20M (-13.07%) | 23M (+4.57%) | 22M (-13.19%) | 25M (-0.76%) | 25M (+17.26%) | 21M (+21.34%) | 18M (-16.06%) | 21M (+30.42%) | 16M (+3.99%) | 16M (+7.85%) | 14M (+44.62%) | 9.95M (+3.97%) | 9.57M (+61.38%) | 5.93M (-17.75%) | 7.21M (-46.63%) | 14M (+405.99%) | 2.67M | - | - |
Depreciation And Amortization | 380K (-15.56%) | 450K (+50.00%) | 300K (0.00%) | 300K (-3.23%) | 310K (+10.71%) | 280K (-6.67%) | 300K (+50.00%) | 200K (-9.09%) | 220K (+4.76%) | 210K (+110.00%) | 100K (0.00%) | 100K (-23.08%) | 130K (+8.33%) | 120K (+20.00%) | 100K (0.00%) | 100K (+100.00%) | 50K (+66.67%) | 30K (+200.00%) | 10K | - | - |
Operating Income | |||||||||||||||||||||
Operating Income | -19.90M (-1.09%) | -20.12M (+2.18%) | -19.69M (-13.07%) | -22.65M (+4.57%) | -21.66M (-13.19%) | -24.95M (-0.76%) | -25.14M (+17.26%) | -21.44M (+21.34%) | -17.67M (-16.06%) | -21.05M (+30.42%) | -16.14M (+3.99%) | -15.52M (+7.85%) | -14.39M (+44.77%) | -9.94M (+3.87%) | -9.57M (+61.66%) | -5.92M (-17.89%) | -7.21M (-46.63%) | -13.51M (+405.99%) | -2.67M | - | - |
Ebit | -19.90M (-1.09%) | -20.12M (+2.18%) | -19.69M (-13.07%) | -22.65M (+4.57%) | -21.66M (-13.19%) | -24.95M (-0.76%) | -25.14M (+17.26%) | -21.44M (+21.34%) | -17.67M (-16.06%) | -21.05M (+30.42%) | -16.14M (+3.99%) | -15.52M (+7.85%) | -14.39M (+44.77%) | -9.94M (+3.87%) | -9.57M (+61.66%) | -5.92M (-17.89%) | -7.21M (+78.02%) | -4.05M (+51.69%) | -2.67M (+4.71%) | -2.55M (-63.10%) | -6.91M |
EBITDA | -19.52M (-0.76%) | -19.67M (+1.44%) | -19.39M (-13.24%) | -22.35M (+4.68%) | -21.35M (-13.46%) | -24.67M (-0.68%) | -24.84M (+16.95%) | -21.24M (+21.79%) | -17.44M (-16.31%) | -20.84M (+29.93%) | -16.04M (+4.02%) | -15.42M (+8.06%) | -14.27M (+45.17%) | -9.83M (+3.80%) | -9.47M (+62.71%) | -5.82M (-18.83%) | -7.17M (+77.92%) | -4.03M (+51.50%) | -2.66M (+4.31%) | -2.55M (-63.10%) | -6.91M |
Other Income / Expenses | |||||||||||||||||||||
Interest Income | - | - | - | - | - | - | - | - | - | 7.00M | - | - | - | 1.50M | - | - | - | - | - | - | - |
Net Interest Income | - | - | - | - | - | - | - | - | - | 7.00M | - | - | - | 1.50M | - | - | - | - | - | - | - |
Other Non Operating Income | -130.00K (-51.85%) | -270.00K (+440.00%) | -50.00K (-44.44%) | -90.00K (+800.00%) | -10.00K (-98.21%) | -560.00K | - | -50.00K (-80.77%) | -260.00K (-18.75%) | -320.00K (+220.00%) | -100.00K (-37.50%) | -160.00K (-5.88%) | -170.00K | 1.49M (+292.11%) | 380K (+245.45%) | 110K | -10.00K | 20K | - | - | - |
Net Income | |||||||||||||||||||||
Income Before Tax | - | -77.82M | - | - | - | -80.44M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income From Continuing Operations | -19.04M (+0.32%) | -18.98M (+4.11%) | -18.23M (-13.23%) | -21.01M (+6.76%) | -19.68M (-13.80%) | -22.83M (+1.74%) | -22.44M (+19.36%) | -18.80M (+14.01%) | -16.49M (-14.34%) | -19.25M (+33.03%) | -14.47M (+4.03%) | -13.91M (+9.01%) | -12.76M (+42.89%) | -8.93M (-2.93%) | -9.20M (+58.08%) | -5.82M (-19.39%) | -7.22M (+66.36%) | -4.34M (+77.87%) | -2.44M (-4.31%) | -2.55M (-63.10%) | -6.91M |
Net Income | -19.04M (+0.32%) | -18.98M (+4.11%) | -18.23M (-13.23%) | -21.01M (+6.76%) | -19.68M (-13.80%) | -22.83M (+1.74%) | -22.44M (+19.36%) | -18.80M (+14.01%) | -16.49M (-14.34%) | -19.25M (+33.03%) | -14.47M (+4.03%) | -13.91M (+9.01%) | -12.76M (+42.89%) | -8.93M (-2.93%) | -9.20M (+58.08%) | -5.82M (-19.39%) | -7.22M (+66.36%) | -4.34M (+77.87%) | -2.44M (-4.31%) | -2.55M (-63.10%) | -6.91M |
Comprehensive Income Net Of Tax | -19.15M (-75.52%) | -78.24M (+329.18%) | -18.23M (-13.93%) | -21.18M (+6.75%) | -19.84M (-75.21%) | -80.03M (+269.82%) | -21.64M (+15.41%) | -18.75M (+13.84%) | -16.47M (-72.72%) | -60.38M (+321.06%) | -14.34M (-0.07%) | -14.35M (+13.44%) | -12.65M (-59.53%) | -31.26M (+235.05%) | -9.33M | - | - | - | - | - | - |